580 related articles for article (PubMed ID: 19122266)
21. [Osteoporosis--new therapeutic possibilities. The Danish Bone Society].
Langdahl BL; Rejnmark L;
Ugeskr Laeger; 2008 Mar; 170(12):1043. PubMed ID: 18397661
[No Abstract] [Full Text] [Related]
22. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Saito M
Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
[No Abstract] [Full Text] [Related]
24. What is the optimal duration of bisphosphonate therapy?
Ott SM
Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
[TBL] [Abstract][Full Text] [Related]
25. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
Nishida A; Ito M
Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
[TBL] [Abstract][Full Text] [Related]
26. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Martens MG; Shaw H
South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
[TBL] [Abstract][Full Text] [Related]
27. [Outline of Guidelines 2004 for bone marker in osteoporosis].
Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():37-41. PubMed ID: 18161079
[No Abstract] [Full Text] [Related]
28. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
29. [Bone diseases with Pain. Osteoporosis].
Hayashi Y
Clin Calcium; 2007 Apr; 17(4):606-12. PubMed ID: 17404492
[TBL] [Abstract][Full Text] [Related]
30. [Evidence of risedronate for treatment of osteoporosis].
Soen S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():344-7. PubMed ID: 18161128
[No Abstract] [Full Text] [Related]
31. [Image assessment of the treatment effect on osteoporosis: bisphosphonates].
Sone T
Clin Calcium; 2011 Jul; 21(7):1041-6. PubMed ID: 21719985
[TBL] [Abstract][Full Text] [Related]
32. [Management of osteoporosis by using biochemical markers for bone turnover].
Mizunuma H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():227-30. PubMed ID: 18159710
[No Abstract] [Full Text] [Related]
33. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Yamada S; Inaba M; Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
[No Abstract] [Full Text] [Related]
34. [Evidence of alendronate treatment for osteoporosis].
Harada A
Nihon Rinsho; 2007 Nov; 65 Suppl 9():337-43. PubMed ID: 18161127
[No Abstract] [Full Text] [Related]
35. [Evaluation of therapeutic intervention on bone mass and turnover through monitoring of biochemical markers of bone turnover].
Ohta H
Nihon Rinsho; 2006 Sep; 64(9):1663-9. PubMed ID: 16972676
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
Tanaka S; Yoshida A; Kono S; Ito M
J Orthop Sci; 2017 May; 22(3):536-541. PubMed ID: 28108224
[TBL] [Abstract][Full Text] [Related]
37. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
38. [Role of pharmaceutical intervention in the treatment of osteoporosis and prevention of fracture].
Nakamura T
Nihon Rinsho; 2009 May; 67(5):903-8. PubMed ID: 19432107
[TBL] [Abstract][Full Text] [Related]
39. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
40. [New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis].
Hagino H
Clin Calcium; 2009 Jan; 19(1):75-84. PubMed ID: 19122267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
